Drug Profile
Research programme: neurodevelopmental disorders therapeutics - Vencerx Therapeutics
Latest Information Update: 28 Apr 2021
Price :
$50
*
At a glance
- Originator Vencerx Therapeutics
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Fragile X syndrome
Most Recent Events
- 28 Apr 2021 No recent reports of development identified for research development in Fragile-X-syndrome in USA
- 31 Mar 2017 Early research in Fragile X syndrome in USA (unspecified route)